COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
复制标题
COX-2表达与原位导管癌中的侵袭性表型有关。
DOI：
10.1038/sj.bjc.6601534
复制
发表时间：
2004-01-26
影响因子：
8.8
通讯作者：
Bundred, N J
中科院分区：
文献类型：
--
作者：
Boland, G P;Butt, I S;Prasad, R;Knox, W F;Bundred, N J
环氧合酶2型（考克斯-2）在恶性肿瘤（包括乳腺癌）中过表达，但上调机制尚不清楚。本研究旨在检测考克斯-2（COX-2）在导管原位癌（DCIS）、浸润性乳腺癌（IBC）和正常乳腺组织中的表达，并探讨考克斯-2表达与HER-2表达、雌激素受体（ER）、肿瘤分级和细胞增殖（Ki 67）的关系。采用免疫组化法检测187例DCIS、65例IBC和60例正常减乳组织中COX-2、HER-2、ER和Ki 67的表达。COX-2在DCIS（67%，P<0.001）和IBC（63%，P<0.001）中的表达明显高于正常乳腺组织（23%，P<0.001）。考克斯-2在DCIS和IBC中的表达差异无统计学意义（P=0.87），在缩小术后的正常乳腺和DCIS周围的正常乳腺导管中的表达差异无统计学意义（22%，P=0.29）。在DCIS中，考克斯-2表达与细胞增殖率（P<0.0001）、核分级（P=0.003）、ER阴性（P=0.003）和HER-2阳性（P<0.0001）相关。原位乳腺癌中环氧合酶2型表达上调，并与侵袭性DCIS表型的替代标记物（包括非雌激素调节的信号传导途径）相关。环氧合酶2型抑制剂可能潜在地预防ER阳性和ER阴性乳腺癌的发展。
Cyclooxygenase type-2 (COX-2) is overexpressed in malignant tumours including breast cancers, though the mechanism of upregulation is unclear. This study aimed to determine COX-2 expression in ductal carcinoma in situ (DCIS) in comparison to invasive breast cancer (IBC) and normal breast, and also to investigate the relationship of COX-2 expression with HER-2 expression, oestrogen receptor (ER), tumour grade and cellular proliferation (Ki67) in DCIS. Cyclooxygenase type-2, HER-2, ER and Ki67 expression were determined by immunohistochemistry on paraffin tissue sections of DCIS (n=187), IBC (n=65) and normal breast reduction tissue (n=60). Cyclooxygenase type-2 expression in DCIS (67%, P<0.001) and IBC (63%, P<0.001) was significantly greater than in normal breast (23%). There was no difference in COX-2 expression level between DCIS and IBC (P=0.87) or between normal breast from reduction mammoplasty tissue and normal breast ducts around DCIS (22%, P=0.29). In DCIS, COX-2 expression was associated with higher cellular proliferation rates (P<0.0001), nuclear grade (P=0.003), with ER negativity (P=0.003) and with HER-2 positivity (P<0.0001). Cyclooxygenase type-2 expression is upregulated in in situ breast cancer and is associated with surrogate markers of an aggressive DCIS phenotype including nonoestrogen-regulated signalling pathways. Cyclooxygenase type-2 inhibition may potentially prevent the development of ER-positive and ER-negative breast cancers.